Hillstream Biopharma (CNTN) versus Its Rivals Head-To-Head Comparison

Hillstream Biopharma (NASDAQ:CNTN) is one of 223 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Hillstream Biopharma to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Hillstream Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Hillstream Biopharma Competitors	-5,512.31%	-256.81%	-48.88%

Valuation & Earnings

This table compares Hillstream Biopharma and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hillstream Biopharma	N/A	-$35.92 million	-2.91
Hillstream Biopharma Competitors	$337.72 million	-$25.05 million	-4.45

Hillstream Biopharma’s peers have higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hillstream Biopharma and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Hillstream Biopharma Competitors	2221	2430	4302	67	2.25

As a group, “Pharmaceutical Preparations” companies have a potential upside of 122.16%. Given Hillstream Biopharma’s peers stronger consensus rating and higher possible upside, analysts plainly believe Hillstream Biopharma has less favorable growth aspects than its peers.

Risk and Volatility

Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Hillstream Biopharma’s peers have a beta of 12.28, suggesting that their average share price is 1,128% more volatile than the S&P 500.

Insider and Institutional Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 31.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Hillstream Biopharma peers beat Hillstream Biopharma on 9 of the 13 factors compared.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.